Company news

Telix Pharmaceuticals Limited (ASX:TLX) news

Telix Pharmaceuticals Limited news releases on 6ix. Latest, Oct 6, 2026: Telix Pharmaceuticals : First Patients Dosed with Telix’s FDA-Approved Brain Cancer…

Telix Pharmaceuticals Limited (ASX:TLX) news

Press releases & updates

Telix Pharmaceuticals : First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara (floretyrosine F 18)

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Telix Pharmaceuticals : Notification of cessation of securities - TLX

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

FDA Approves Telix Brain Cancer Imaging Drug Pixclara

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

Telix Appoints David Gill as Chair

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

Telix to Host R&D Day in New York City on September 22, 2026

Telix H1 2026 Results: Investor Webcast Notification

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing

Telix Pharmaceuticals : Notification of cessation of securities - TLX

FDA Alignment to Advance ProstACT Global Phase 3 Trial

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026

Telix and United Imaging Announce Strategic Theranostics Collaboration

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

TLX101-Px (Pixlumi®) MAA Accepted in Europe

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

Telix Successfully Prices Upsized US$600M Convertible Bonds

Telix Investor Presentation April 2026

Telix Refinances Convertible Bonds

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Regeneron and Telix Announce Strategic Radiopharma Collaboration

Telix and Regeneron Announce Radiopharma Collaboration

FDA Accepts NDA for TLX101-Px (Pixclara)

Telix Strengthens Board with Additional Director Appointments

Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement

Telix Appoints David Gill as Non-Executive Director

Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.

Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate

Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging

ProstACT Global Phase 3 (Part 1) Results Presentation

ProstACT Global Phase 3 (Part 1) Achieves Primary Objectives

Investor Education Webinar

Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging